Clonal Upregulation of Effector Cytotoxic T Lymphocytes in a Patient with Multiple Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia with Long-Term Survival

We present the case of a patient with multiple tyrosine kinase inhibitor (TKI)-refractory chronic phase chronic myeloid leukemia (CP-CML) with a T315I mutation of abl1. Dasatinib, a second-generation TKI, was administered as the initial treatment but achieved neither a cytogenetic nor molecular resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Tatsuro, Sakai, Takahiro, Matsuzaka, Kaori, Noguchi, Kazuhiro, Hayashi, Shizuka, Matsuo, Masatoshi, Taguchi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077377/
https://www.ncbi.nlm.nih.gov/pubmed/33976626
http://dx.doi.org/10.1159/000514631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077377/
https://www.ncbi.nlm.nih.gov/pubmed/33976626
http://dx.doi.org/10.1159/000514631

Ejemplares similares